North China Pharmaceuticals for the "payment" of 54.93 million

Pharmaceutical Network January 12, because of the haze stopped production for more than a month, January 9 evening, North China Pharmaceutical sinsaid that the company and some of its subsidiaries previously discontinued part of the business has been started to resume productionHowever, the shutdown has caused some impact on the company's normal production and operation activitiesAccording to preliminary statistics, the depreciation of fixed assets, labor costs and other related expenses will reduce the company's 2016 profit of 54.93 million yuanafter a number of Shijiazhuang pharmaceutical companies, including North China Pharmaceuticals, stopped production at the request of the local government because of heavy air pollutionOn November 21, 2016, North China Pharmaceuticals issued a "tip announcement on the discontinuation of production of the company and some sub-sub(sub)companies," saying that the company and some of its subsidiaries (sub-sub)companies received the "Shijiazhuang City Air Pollution Prevention and Control Dispatch Order", requiring all pharmaceutical enterprises in the city to stop production, without the approval of the municipal government can not resume productionAt that time, the company expected that the raw materials part will affect the company's current profit of about 50 million yuanNorth China Pharmaceuticals said that if the company's relevant units during this period to maintain normal production, according to the actual operating conditions are expected to stop production period can achieve a profit of about 11 million yuanthe pharmaceutical industry has always been a big polluterIt is understood that China's pharmaceutical industry to create industrial output value accounted for 2.1% of the country's total industrial output, and its wastewater emissions and COD emissions accounted for about 3% of the country's industrial emissionsAccording to Zhang Mingxuan, senior vice president of the China Chemical and Pharmaceutical Industry Association, in 2014, the state key monitoring enterprises for wastewater 4001, itsChinese medicinemanufacturing enterprises have 118, about 2.9
%;the production process of raw materials, the amount of waste gas, waste water, waste residue is large, the waste component is complex, for the environment and human bodyhealthharm is more serious, and thus make the pharmaceutical enterprises more serious environmental situation, and there are pharmaceutical enterprises due to environmental non-standard severity is required to limit production or stop productionIn recent years, the pharmaceutical companies involved in environmental issues are not in the minority, Kazakhstan Pharmaceuticals, Yunnan Pharmaceuticals, Federal Pharmaceuticals, Haizheng Pharmaceuticals and other large pharmaceutical companies have been inspected by environmental protection departments to rectify however, the pharmaceutical industry has been the environmental protection problems will be expected to be centralized this year At the end of last year, the Supreme People's Court and the Supreme People's Procuratorate issued judicial interpretations of criminal cases of environmental pollution, including the alteration, falsification of automatic monitoring data or interference with automatic monitoring facilities by key sewage units, and the discharge of chemical oxygen demand, ammonia nitrogen, sulfur dioxide, nitrogen oxides and other pollutants, which should be considered as "serious pollution of the environment"; The crime of destroying computer information system is punished for modifying environmental parameters or monitoring data Beijing Dingchen Pharmaceutical Management Advisory Center head Shi Lichen in an interview with the media had expected that the cost of medicine enterprises pollution treatment is very high, to spend hundreds of millions of yuan or more, in the past in the environmental law enforcement is not strong, enterprises are often willing to be fined and not willing to carry out environmental investment;